VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection

Viral Immunology

Volumn 28, Issue 1, 2015, Pages 51-61

  Williams, Kinola J N ^a   Qiu, Xiangguo ^b   Fernando, Lisa ^b   Jones, Steven M ^c   Alimonti, Judie B ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c Cognoveritas Consulting Inc ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; DRUG CARRIER; EBOLA VACCINE; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INNATE IMMUNITY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; VESICULOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CYTOTOXICITY TEST; DISEASE MODEL; EBOLAVIRUS; GENE VECTOR; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; KNOCKOUT MOUSE; SECRETION (PROCESS); SURVIVAL;

ANIMALIA; CAVIA; EBOLA VIRUS; MUS; PRIMATES; ZAIRE EBOLAVIRUS;

ANIMALS; ANTIGENS, VIRAL; CYTOTOXICITY TESTS, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EBOLA VACCINES; EBOLAVIRUS; FEMALE; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MALE; MICE, INBRED BALB C; MICE, KNOCKOUT; SURVIVAL ANALYSIS; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS;

EID: 84920774305     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2014.0069     Document Type: Article

References (45)

1. Ahmed M, Cramer S D, and Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 2004;330:34-49.
2. Ahmed M, Mitchell LM, Puckett S, et al. Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and-independent mechanisms. J Virol 2009;83:2962-2975.
3. Baize S. A single shot against Ebola and Marburg virus. Nat Med 2005;11:720-721.
4. Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002;128:163-168.
5. Barna M, Komatsu T, Bi Z, et al. Sex differences in susceptibility to viral infection of the central nervous system. J Neuroimmunol 1996;67:31-39.
6. Basler CF, Wang X, Muhlberger E, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 2000;97:12289-12294.
7. Bi Z, Barna M, Komatsu T, et al. Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol 1995;69:6466-6472.
8. Bradfute SB, Dye JM Jr, and Bavari S. Filovirus vaccines. Hum Vaccin 2011;7:701-711.
9. Bray M, Davis K, Geisbert T, et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998;178:651-661.
10. Colucci F, Caligiuri MA, and Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol 2003;3: 413-425.
11. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399-1404.
12. Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006;2:e73.
13. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007;3:e2.
14. Feldmann H, Sanchez A, and Klenk H. Filoviruses. 9th ed. Vol. 1. London: Edward Arnold, 1997.
15. Friedrich BM, Trefry JC, Biggins JE, et al. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 2012;4:1619-1650.
16. Fuller CL, Ruthel G, Warfield KL, et al. NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell Microbiol 2007;9:962-976.
17. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004;78:5458-5465.
18. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008;26:6894-6900.
19. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008;82: 5664-5648.
20. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003;163:2347-2370.
21. Gomez-Roman VR, Florese RH, Patterson LJ, et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 2006;308:53-67.
22. Halfmann P, Neumann G, and Kawaoka Y. The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogenactivated protein kinase. J Infect Dis 2011;204:S953-956.
23. Harcourt BH, Sanchez A, and Offermann MK. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol 1999;73: 3491-3496.
24. Ignatiev GM, Dadaeva AA, Luchko SV, et al. Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs. Immunol Lett 2000;71:131-140.
25. Ito Y, and Montagnier L. Heterogeneity of the sensitivity of vesicular stomatitis virus to interferons. Infect Immun 1977;18:23-27.
26. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11:786-790.
27. Jones SM, Stroher U, Fernando L, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007;196:S404-412.
28. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-713.
29. MacNeil A, and Rollin PE. Ebola and Marburg hemorrhagic fevers: neglected tropical diseases? PLoS Negl Trop Dis 2012;6:e1546.
30. Mahanty S, and Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004;4:487-498.
31. Mian MF, Lauzon NM, Andrews DW, et al. FimH can directly activate human and murine natural killer cells via TLR4. Mol Ther 2010;18:1379-1388.
32. Mohamadzadeh M. Potential factors induced by filoviruses that lead to immune supression. Curr Mol Med 2009;9:174-185.
33. Mohamadzadeh M, Chen L, Olinger GG, et al. Filoviruses and the balance of innate, adaptive, and inflammatory responses. Viral Immunol 2006;19:602-612.
34. Nishikado H, Mukai K, Kawano Y, et al. NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J Immunol 2011;186:5766-5771.
35. Okumura A, Pitha PM, Yoshimura A, et al. Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol 2010;84:27-33.
36. Peters CJ. Emerging infections-Ebola and other filoviruses. West J Med 1996;164:36-38.
37. Ramanan P, Shabman RS, Brown CS, et al. Filoviral immune evasion mechanisms. Viruses 2011;3:1634-1649.
38. Reed DS, Hensley LE, Geisbert JB, et al. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol 2004;17:390-400.
39. Scotland RS, Stables MJ, Madalli S, et al. Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice. Blood 2012; 118:5918-5927.
40. Simmons G, Wool-Lewis RJ, Baribaud F, et al. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 2002;76:2518-2528.
41. Smyth MJ, Cretney E, Kelly JM, et al. Activation of NK cell cytotoxicity. Mol Immunol 2005;42:501-510.
42. Sullivan NJ, Peterson M, Yang ZY, et al. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol 2005;79:547-553.
43. Warfield KL, Perkins JG, Swenson DL, et al. Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 2004;200:169-179.
44. Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014;32:5722-5729.
45. Yokoyama WM, Kim S, and French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004;22: 405-429.